{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:04:12Z","timestamp":1788393852650,"version":"build-2803163510"},"reference-count":27,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for relapsed or refractory multiple myeloma (RRMM), with high response rates of 80\u201395%. Serum immunoglobulin changes have been observed throughout conventional multiple myeloma treatment, including after immunomodulatory drugs, proteasome inhibitors, and autologous stem cell transplantation. However, the clinical significance of new abnormal protein bands (APBs) following CAR T-cell therapy is largely unexplored. We retrospectively analyzed consecutive multiple myeloma (MM) patients who received CAR T-cell therapy at the University Hospital Bern between May 2021 and February 2024. Serum paraprotein (M-protein) patterns were assessed using immuno-fixation electrophoresis (IFE) before and after CAR T-cell treatment. Patients were grouped based on serum immunoglobulin changes. Among 46 patients, 9 (19.6%) developed new APBs following CAR T-cell therapy. No significant differences in overall survival (OS) or progression-free survival (PFS) were observed between patients with and without APBs. Immunoglobulin changes occurred in both relapsed and non-relapsed patients, suggesting that the appearance of new APBs does not indicate disease progression. This observation aligns with previous reports of paraprotein changes following conventional MM therapies. This report suggests that new APBs following CAR T-cell therapy are a relatively common finding but do not correlate with inferior clinical outcomes. Our results highlight the need for larger, multi-center studies to further investigate this phenomenon in MM patients undergoing CAR T-cell therapy.<\/jats:p>","DOI":"10.3390\/cimb47080640","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T09:59:13Z","timestamp":1754906353000},"page":"640","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum Immunoglobulin Changes in Multiple Myeloma Patients Treated with CAR T-Cell Therapy"],"prefix":"10.3390","volume":"47","author":[{"given":"Alexa","family":"Burger","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-1573","authenticated-orcid":false,"given":"Katja","family":"Seipel","sequence":"additional","affiliation":[{"name":"Department for Biomedical Research (DBMR), University of Bern, CH-3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-827X","authenticated-orcid":false,"given":"Christof","family":"Schild","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Shaforostova","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cpt.2022.11.002","article-title":"Clinical Characteristics and Prognostic Significance of Immunoglobulin Isotype Switch in Patients with Multiple Myeloma","volume":"1","author":"Lu","year":"2023","journal-title":"Cancer Pathog. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory Trial of a Biepitopic CAR T-Targeting B Cell Maturation Antigen in Relapsed\/Refractory Multiple Myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T Therapies in Multiple Myeloma: Unleashing the Future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_8","first-page":"225","article-title":"Isotype Class Switching after Transplantation in Multiple Myeloma","volume":"54","author":"Maisnar","year":"2007","journal-title":"Neoplasma"},{"key":"ref_9","first-page":"113","article-title":"Significance of Abnormal Protein Bands in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation","volume":"30","author":"Hall","year":"2009","journal-title":"Clin. Biochem. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3324\/haematol.2010.030882","article-title":"Emergence of Oligoclonal Bands in Patients with Multiple Myeloma in Complete Remission after Induction Chemotherapy: Association with the Use of Novel Agents","volume":"96","author":"Tovar","year":"2011","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2141.2008.07374.x","article-title":"Atypical Serum Immunofixation Patterns Frequently Emerge in Immunomodulatory Therapy and Are Associated with a High Degree of Response in Multiple Myeloma","volume":"143","author":"Mark","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bjh.18500","article-title":"Multiple Immunoglobulin Isotype Switch after Bispecific CAR-T Cell Therapy in Multiple Myeloma-A Case Report","volume":"200","author":"Li","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/bloodadvances.2021005814","article-title":"Immunoglobulin Isotype Switch after Anti-BCMA CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma","volume":"6","author":"Liang","year":"2022","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"K\u00fcndgen, L.J., Akhoundova, D., Hoffmann, M., Legros, M., Shaforostova, I., Seipel, K., Bacher, U., and Pabst, T. (2025). Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients. Cancers, 17.","DOI":"10.3390\/cancers17091565"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High Efficacy and Safety of CD38 and BCMA Bispecific CAR-T in Relapsed or Refractory Multiple Myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_16","first-page":"100276","article-title":"Secondary Monoclonal Gammopathy of Unknown Significance with Isotype Switching after CAR T-Cell Therapy for Multiple Myeloma: A Case Report","volume":"13","author":"Kalariya","year":"2024","journal-title":"Curr. Probl. Cancer Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e70070","DOI":"10.1002\/hem3.70070","article-title":"Idecabtagene Vicleucel or Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma: An International Multicenter Study","volume":"9","author":"Merz","year":"2025","journal-title":"HemaSphere"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and Clinical Efficacy of BCMA CAR-T-Cell Therapy in Multiple Myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/j.clml.2018.12.022","article-title":"Immune Signatures Associated with Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma","volume":"19","author":"Ye","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107641","DOI":"10.1016\/j.leukres.2025.107641","article-title":"The Presence of Clonal Isotype Switch after Autologous Stem Cell Transplantation as a Prognostic Biomarker for Long-Term Survival in Patients with Multiple Myeloma","volume":"149","author":"Cho","year":"2025","journal-title":"Leuk. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e70054","DOI":"10.1002\/hem3.70054","article-title":"The Incidence and Clinical Significance of Monoclonal and Oligoclonal Protein Bands in Multiple Myeloma Patients after BCMA\u2013CAR-T Cell Therapy: A Retrospective Study Based on LEGEND-2","volume":"8","author":"Liu","year":"2024","journal-title":"HemaSphere"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/blood-2008-01-129221","article-title":"Analysis of Clonotypic Switch Junctions Reveals Multiple Myeloma Originates from a Single Class Switch Event with Ongoing Mutation in the Isotype-Switched Progeny","volume":"112","author":"Taylor","year":"2008","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood.V98.9.2791","article-title":"Persistent Preswitch Clonotypic Myeloma Cells Correlate with Decreased Survival: Evidence for Isotype Switching within the Myeloma Clone","volume":"98","author":"Reiman","year":"2001","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1182\/blood.V91.9.3518","article-title":"Oligoclonal Protein Bands and Ig Isotype Switching in Multiple Myeloma Treated with High-Dose Therapy and Hematopoietic Cell Transplantation","volume":"91","author":"Zent","year":"1998","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood.V74.8.2764.2764","article-title":"Monoclonal and Oligoclonal Gammopathy after Bone Marrow Transplantation","volume":"74","author":"Mitus","year":"1989","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral Immune Reconstitution after Anti-BCMA CAR T-Cell Therapy in Relapsed\/Refractory Multiple Myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/8\/640\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:27:20Z","timestamp":1760034440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/8\/640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cimb47080640"],"URL":"https:\/\/doi.org\/10.3390\/cimb47080640","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]}}}